Do we have suitable in-vitro diagnostic tests for the diagnosis of food allergy?

2004 ◽  
Vol 4 (3) ◽  
pp. 211-213 ◽  
Author(s):  
Philippe A Eigenmann
Keyword(s):  
Food Allergy ◽  
Diagnostic Tests ◽  
In Vitro Diagnostic

scholarly journals The influence of sugar–protein complexes on the thermostability of C-reactive protein (CRP)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Andreea Lorena Mateescu ◽  
Nicolae-Bogdan Mincu ◽  
Silvana Vasilca ◽  
Roxana Apetrei ◽  
Diana Stan ◽  
...  
Keyword(s):  
Diagnostic Tests ◽  
Protein Complexes ◽  
C Reactive Protein ◽  
Time Resolved Fluorescence ◽  
Time Resolved ◽  
Reactive Protein ◽  
In Vitro Diagnostic ◽  
The Stability ◽  
Positive Controls

AbstractThe purpose of the present study was to evaluate de influence of protein–sugar complexation on the stability and functionality of C-reactive protein, after exposure to constant high temperatures, in order to develop highly stable positive controls for in-vitro diagnostic tests. C-reactive protein is a plasmatic protein used as a biomarker for the diagnosis of a series of health problems such as ulcerative colitis, cardiovascular diseases, metabolic syndrome, due to its essential role in the evolution of chronic inflammation. The sugar–protein interaction was investigated using steady state and time resolved fluorescence. The results revealed that there are more than two classes of tryptophan, with different degree of accessibility for the quencher molecule. Our study also revealed that sugar–protein complexes have superior thermostability, especially after gamma irradiation at 2 kGy, the protein being stable and functional even after 22 days exposure to 40 °C.

scholarly journals The Clinical Review Committee: Impact of the Development of In Vitro Diagnostic Tests for SARS-CoV-2 Within RADx Tech

2021 ◽  
Vol 2 ◽  
pp. 138-141
Author(s):  
Matthew Robinson ◽  
Charlotte Gaydos ◽  
Barbara Van Der Pol ◽  
Sally McFall ◽  
Yu-Hsiang Hsieh ◽  
...  
Keyword(s):  
Clinical Review ◽  
Diagnostic Tests ◽  
Review Committee ◽  
In Vitro Diagnostic

Japanese healthcare system: in vitro diagnostic tests and reimbursements

1994 ◽  
Vol 40 (8) ◽  
pp. 1663-1667 ◽  
Author(s):  
A Shimauchi
Keyword(s):  
Healthcare System ◽  
Prescription Drugs ◽  
Diagnostic Tests ◽  
Diagnostic Testing ◽  
Universal Coverage ◽  
Medical Expenditures ◽  
National Medical ◽  
Dental Procedures ◽  
In Vitro Diagnostic

Abstract In 1961, a new and mandatory National Health Insurance plan was enacted in Japan. This healthcare system has succeeded in providing universal coverage while also containing the growth of national medical expenditures (NME) to the rate of growth of the gross national product (GNP), namely, approximately 4-5% annually, for several decades. All Japanese medical procedures, including dental procedures, prescription drugs, and diagnostic tests, are reimbursed by a fee schedule set by the Ministry of Health and Welfare. The combination of strict fee control and low administration costs has kept the Japanese NME growth below that of the GNP. In 1990, NME was 20.6 trillion yen ($187 billion), total diagnostic testing expenditures (DTE) were 2.3 trillion yen, representing 11.2% of national medical expenditures (NME). Of this amount, in vitro diagnostic testing accounted for 1.4 trillion yen, representing 61% of DTE and 6.8% of NME. Annually, 1.8 billion in vitro diagnostic tests are performed.

COVID-19 Diagnostic Testing: Lessons Learned for Innovative Product Development During A Public Health Emergency

2020 ◽  
Vol 25 (3) ◽  
Author(s):  
Christopher Lamb
Keyword(s):  
Public Health ◽  
Diagnostic Tests ◽  
Financial Incentives ◽  
Diagnostic Testing ◽  
Adaptive Immune Response ◽  
Lessons Learned ◽  
In Vitro Assays ◽  
Health Crisis ◽  
In Vitro Diagnostic

In response to the Coronavirus Disease-2019 (COVID-19) pandemic, the U.S. Food and Drug Administration (FDA) used its emergency authority through Emergency Use Authorizations (EUAs) to make COVID-19 in vitro diagnostic tests widely available to both diagnose active infection and help identify individuals with an adaptive immune response indicating recent or prior infection. Hundreds of innovative tests were quickly developed under Section IV.D. of FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019. National reimbursement guidance through Centers for Medicare & Medicaid Services (CMS) provided significant financial incentives to track the endemic and enable healthcare workers and others get back to work more quickly. The US market for tests grew rapidly and the now exceeds $15 billion. However, many issues regarding product quality and availability have plagued the industry and called into question FDA’s policy and regulatory framework for allowing these tests to be commercially available. This paper analyzes the development of COVID-19 in vitro assays and the lessons learned for innovation during a public health crisis.

scholarly journals Lot-to-Lot Reproducibility of Standardized Allergen Extracts in IgE In Vitro Diagnostic Tests

2020 ◽  
Vol 145 (2) ◽  
pp. AB151
Author(s):  
Lauren Dinh ◽  
Edsel Sinson ◽  
Steven Nguyen ◽  
Cindy Liao ◽  
Kelline Rodems
Keyword(s):  
Diagnostic Tests ◽  
In Vitro Diagnostic ◽  
Allergen Extracts

scholarly journals DIAGNOSIS OF DELAYED DRUG ALLERGIC REACTIONS

2017 ◽  
Vol 14 (6) ◽  
pp. 7-20
Author(s):  
T S Romanova ◽  
T N Myasnikova ◽  
L V Khludova ◽  
V G Smirnov ◽  
T V Latysheva
Keyword(s):  
Immune Response ◽  
Diagnostic Tests ◽  
Drug Allergy ◽  
Allergic Reactions ◽  
Review Of Literature ◽  
Treatment Efficiency ◽  
Causative Drug ◽  
In Vitro Diagnostic ◽  
Drug Influence

Mechanisms of delayed druginduced allergies (DDIA), individual features of the immune response to the drug, influence of various cofactors (concomitant pathology, viral infection, insolation, etc.) create difficulties in diagnostics of drug allergy (DA). Identification and elimination of a causative drug allows to prevent the development of severe allergic reactions. Verification of DA diagnosis during the survey allows to avoid the unreasonable lifelong ban on application of certain drug, which often leads to decreasing of treatment efficiency and increasing its cost. In vitro diagnostic tests are safe, but laborious and expensive. This article will provide the review of literature, reflecting a modern view on the diagnosis of DDIA.

Sign in / Sign up

Export Citation Format

Share Document